• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Beam Therapeutics Inc. (Amendment)

    2/13/24 5:00:53 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BEAM alert in real time by email
    SC 13G/A 1 tv0415-beamtherapeuticsinc.htm SCHEDULE 13G/A beamtherapeuticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Beam Therapeutics Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  07373V105

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  07373V105

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    123,986

    7.  SOLE DISPOSITIVE POWER

    6,968,129

    8.  SHARED DISPOSITIVE POWER

    196,714

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,164,843

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.79%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Beam Therapeutics Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    238 Main Street, 9th floor
    Cambridge, MA 02142-1016

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    07373V105

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $BEAM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BEAM

    DatePrice TargetRatingAnalyst
    3/28/2025$42.00Neutral → Buy
    BofA Securities
    3/10/2025$40.00Sector Perform → Sector Outperform
    Scotiabank
    1/29/2025Neutral → Overweight
    Cantor Fitzgerald
    11/6/2024$27.00 → $39.00Market Perform → Outperform
    Leerink Partners
    10/16/2024Sector Outperform
    Scotiabank
    7/23/2024$80.00Buy
    H.C. Wainwright
    1/29/2024$38.00 → $40.00Neutral → Overweight
    JP Morgan
    12/15/2023$35.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $BEAM
    SEC Filings

    See more
    • Beam Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Beam Therapeutics Inc. (0001745999) (Filer)

      6/6/25 4:05:16 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

      SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      5/15/25 5:04:40 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

      SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      5/13/25 3:45:40 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Leadership Updates

    Live Leadership Updates

    See more
    • Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

      CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

      12/6/24 7:00:00 AM ET
      $ASRT
      $BEAM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

      CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions. "We are thrilled to welcome Chirfi to our board, bringing in yet another exceptionally talented and experienced biopharma leader to o

      12/4/24 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

      CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors. "Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering d

      12/14/23 6:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Walsh Kathleen E

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:30 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shaw Christi

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:26 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Fishman Mark

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:28 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Beam Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded Beam Therapeutics from Neutral to Buy and set a new price target of $42.00

      3/28/25 8:10:19 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Scotiabank with a new price target

      Scotiabank upgraded Beam Therapeutics from Sector Perform to Sector Outperform and set a new price target of $40.00

      3/10/25 11:54:09 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Beam Therapeutics from Neutral to Overweight

      1/29/25 7:35:38 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

      Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

      6/13/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

      CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). "Sickle cell disease is a devasting disorder that affects approximately 100,000 people in the U.S., leading to anemia, severe pain, stroke and even early death. Receiving orphan drug designation from the FDA emphasizes the importance of new treatment options for this debilitating disease, a

      6/3/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

      CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effecti

      5/29/25 4:01:00 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Financials

    Live finance-specific insights

    See more
    • Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

      Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

      6/13/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

      Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational ge

      5/14/25 9:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

      Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference

      3/10/25 6:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      11/12/24 9:50:15 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      11/7/24 9:56:02 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      10/17/24 11:50:15 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care